- Cullinan Oncology Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed TranscriptFeb 14, 2023
- Cullinan Oncology Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call TranscriptMay 12, 2022
- Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 13, 2022
- Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar TranscriptMar 28, 2022
- Cullinan Oncology Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Cullinan Oncology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call TranscriptDec 16, 2021
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cullinan Oncology Inc Pearl Clinical Update Call TranscriptJun 04, 2021
Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call Transcript
Good morning, everyone, and welcome to the Cullinan Oncology webinar to discuss updated clinical data for our lead program, CLN-081. Earlier this morning, we issued a press release providing an overview of the data, which can be accessed on the Investors section of our website at investors.cullinanoncology.com.
During today's presentation, management will be making certain forward-looking statements, as outlined on this slide. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties, which may cause actual results to differ materially from those contained in such forward-looking statements. These risks are described more fully in the company's filings made with the Securities and Exchange Commission, including our annual report on Form 10-K. You are cautioned not to place any undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
In addition, this call contains time-sensitive information, accurate only as of the date
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)